Impact of von Willebrand Disease on Costs and Patient Outcomes - Featuring a Patient Perspective

Impact of von Willebrand Disease on Costs and Patient Outcomes - Featuring a Patient Perspective is organized by Pharmacy Times Continuing Education (PTCE). This Conference has been approved for a maximum of 1.5 contact hours (0.15 CEUs).

Target Audience: Pharmacists, Specialty Pharmacist and Managed Care Professionals
Length of Webinar: 1.5 hours
Fee: Free

Activity Overview:
Von Willebrand disease (VWD) is the most prevalent bleeding disorder and affects up to 1% of the population worldwide. This activity will differentiate between current von Willebrand factors and delve into managed care and specialty pharmacy approaches to manage both the disease and its costs. Integrated with this discussion will be the addition of a patient perspective that will provide insight on the experience of being diagnosed, starting new therapies, and obtaining access to these medications.

Educational Objectives:
Upon completion of this educational activity, participants will be able to:
• Explain the pathophysiology of VWD and impact it has on healthcare utilization
• Differentiate new and emerging VWD factors based on clinical data and appropriate use
• Examine managed care and specialty pharmacy approaches to ensure appropriate access and medication management of VWD therapies
• Explore available HEOR outcomes data for patients and populations with VWD 

Additional details will be posted as soon as information is available.